Rheinland Biometrics Clears "Pseudo-Influenza Concept"

On the eve of the Ching Ming Festival, the H7N9 bird flu makes a difference, and some investors who smelled the opportunity began to stir up the stocks related to the vaccine concept. The stock prices of Rheinlandia, Lianhuan Pharmaceutical, and Neptunus Biologicals both rose sharply.

On the evening of April 7, the three companies mentioned above issued announcements in an unanimous manner, all clearing out the relationship with the bird flu. Among them, Rheinland Biologicals, which has repeatedly become a “false flu concept”, has stated clearly that “Since its establishment, the company has never been involved in the research, development, production, or sales of vaccines or diagnostic reagents. At present, the company’s products and the flu drugs are not in existence. Correlation."

In contrast to the above three companies, Yiling Pharmaceutical also issued an announcement yesterday evening that the company received a notice on April 3, 2013 that the company’s products, Lianhua Qingqi capsules, were listed on the National Health and Family Planning Commission. "Human infection of H7N9 bird flu treatment program (1st edition in 2013)".

The three companies clarified that Lianhua Pharmaceutical had consulted the management of the company, the controlling shareholder Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. and the actual controller Jiangsu Jinmao Chemical Pharmaceutical Group Co., Ltd., in addition to the disclosed major assets reorganization, There are no major issues affecting the fluctuation of the stock price of the company within the next three months, including but not limited to other major issues involving the transfer of company equity, non-public offerings, debt restructuring, business restructuring, divestitures, or asset injection.

Hai Wang biological said, the company noted that the recent public media reported cases of human infection with H7N9 bird flu in the country, including the company's stock price of a number of pharmaceutical listed companies rose in different ranges. According to verification, the company does not currently produce influenza vaccine products, nor has it developed H7N9 bird flu-related vaccine products.

Compared with the first two companies, Rheinlandia has been plagued with difficulties. The company stated that it has never been involved in the research, development, production, or sales of vaccines or diagnostic reagents. At present, there is no correlation between the products produced by the company and the treatment of influenza drugs.